

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and National Director of Research, Support and Education Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial for the investigational drug, BI 425809. This trial will determine if the investigational drug is safe and effective for improving cognition in individuals with schizophrenia. Study participants will be randomly assigned to receive either the investigational drug or placebo in addition to their current schizophrenia medications over the course of six months. The goal of this study is to increase treatment options available for people with schizophrenia who are experiencing cognitive impairment.

WHO CAN PARTICIPATE?

To pre-qualify for the study, individuals must:

- Be 18-50 years of age at the time of joining the study and diagnosed with schizophrenia
- Have been taking the same medication for schizophrenia for at least three months
- Experience trouble with cognitive tasks, such as remembering things or staying focused
- Be able to attend study visits with someone they see and speak to regularly (a study partner)
- Not have been hospitalized for symptoms related to schizophrenia within the last three months or have had suicidal behavior in the past year

There will be about 1800 people with schizophrenia and about 1800 study partners participating in this study world-wide. Total participation time, including screening and follow-up, is about eight months.

WHERE IS THE STUDY TAKING PLACE?

There are multiple study sites located across the U.S. For a list of study site locations, please visit the study website: <http://www.connexresearchstudy.com/>.

HOW DO I LEARN MORE?

If you have questions or would like more information, please refer to the study website: <http://www.connexresearchstudy.com/>.